Table 3.
Response to second-generation tyrosine kinase inhibitors (dasatinib, nilotinib and bosutinib) in patients whose condition is imatinib resistant or who are intolerant in chronic myelogenous leukemia CP, AP and BP.
| Dasatinib |
Nilotinib |
Bosutinib |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CP n = 387 | AP n = 174 | MyBP n = 109 | LyBP n = 48 | CP n = 321 | AP n = 137 | MyBP n = 105 | LyBP n = 31 | CP n = 146 | AP n = 51 | BP n = 38 | |
| Median follow up (months) | 15 | 14 | 12+ | 12+ | 24 | 9 | 3 | 3 | 7 | 6 | 3 |
| Resistant to imatinib (%) | 74 | 93 | 91 | 88 | 70 | 80 | 82 | 82 | 69 | NR | NR |
| Hematologic response (%) | – | 79 | 50 | 40 | 94 | 56 | 22 | 19 | 85 | 54 | 36 |
| CHR (%) | 91 | 45 | 27 | 29 | 76 | 31 | 11 | 13 | 81 | 54 | 36 |
| NEL (%) | – | 19 | 7 | 6 | – | 12 | 1 | 0 | – | 0 | 0 |
| Cytogenetic response (%) | NR | 44 | 36 | 52 | NR | NR | NR | NR | – | NR | NR |
| Complete (%) | 49 | 32 | 26 | 46 | 46 | 20 | 29 | 32 | 34 | 27 | 35 |
| Partial (%) | 11 | 7 | 7 | 6 | 15 | 12 | 10 | 16 | 13 | 20 | 18 |
| Survival (%) (at 12 months) | 96 (15) | 82 (12) | 50 (12) | 50 (5) | 87 (24) | 67 (24) | 42 (12) | 42 (12) | 98 (12) | 60 (12) | 50 (10) |
[Brave et al. 2008; Hochhaus et al. 2009a].
AP, accelerated phase; CHR, complete hematologic response; CP, chronic phase; LyBP, lymphoid blast phase; MyBP, myeloid blast phase; NEL, no evidence of leukemia; NR, not reported.